JPWO2021256555A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021256555A5 JPWO2021256555A5 JP2022531930A JP2022531930A JPWO2021256555A5 JP WO2021256555 A5 JPWO2021256555 A5 JP WO2021256555A5 JP 2022531930 A JP2022531930 A JP 2022531930A JP 2022531930 A JP2022531930 A JP 2022531930A JP WO2021256555 A5 JPWO2021256555 A5 JP WO2021256555A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- pharmaceutical composition
- cell antigen
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims 35
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000003246 corticosteroid Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000010956 Glypican Human genes 0.000 claims 4
- 108050001154 Glypican Proteins 0.000 claims 4
- 108050007237 Glypican-3 Proteins 0.000 claims 4
- 206010052015 cytokine release syndrome Diseases 0.000 claims 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 102100032530 Glypican-3 Human genes 0.000 claims 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 229960002833 aflibercept Drugs 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 230000008472 epithelial growth Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002633 ramucirumab Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023043678A JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020106501 | 2020-06-19 | ||
| JP2020106501 | 2020-06-19 | ||
| PCT/JP2021/023149 WO2021256555A1 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043678A Division JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021256555A1 JPWO2021256555A1 (https=) | 2021-12-23 |
| JPWO2021256555A5 true JPWO2021256555A5 (https=) | 2022-11-25 |
| JP7250219B2 JP7250219B2 (ja) | 2023-03-31 |
Family
ID=79268097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531930A Active JP7250219B2 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
| JP2023043678A Withdrawn JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043678A Withdrawn JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230235056A1 (https=) |
| EP (1) | EP4186527A4 (https=) |
| JP (2) | JP7250219B2 (https=) |
| KR (2) | KR20230152789A (https=) |
| CN (1) | CN115768478A (https=) |
| AU (1) | AU2021292932A1 (https=) |
| BR (1) | BR112022025536A2 (https=) |
| CA (1) | CA3180951A1 (https=) |
| CL (1) | CL2022003622A1 (https=) |
| CR (1) | CR20230014A (https=) |
| IL (1) | IL299127A (https=) |
| MX (1) | MX2022015764A (https=) |
| PE (1) | PE20230435A1 (https=) |
| TW (1) | TW202214286A (https=) |
| WO (1) | WO2021256555A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025167982A1 (zh) * | 2024-02-08 | 2025-08-14 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物和抗vegf抗体的联合应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773719A (en) | 1966-12-06 | 1973-11-20 | Hoffmann La Roche | 2-aminoxy-2'-acyl-acetanilide |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US8337854B2 (en) | 2007-04-04 | 2012-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in Fc region |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| CN118440206A (zh) | 2014-04-07 | 2024-08-06 | 中外制药株式会社 | 免疫活化抗原结合分子 |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US11072666B2 (en) * | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物 |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
-
2021
- 2021-06-18 PE PE2022002932A patent/PE20230435A1/es unknown
- 2021-06-18 US US18/010,615 patent/US20230235056A1/en active Pending
- 2021-06-18 MX MX2022015764A patent/MX2022015764A/es unknown
- 2021-06-18 IL IL299127A patent/IL299127A/en unknown
- 2021-06-18 CA CA3180951A patent/CA3180951A1/en active Pending
- 2021-06-18 TW TW110122300A patent/TW202214286A/zh unknown
- 2021-06-18 CN CN202180043015.4A patent/CN115768478A/zh active Pending
- 2021-06-18 KR KR1020237036198A patent/KR20230152789A/ko active Pending
- 2021-06-18 EP EP21825999.2A patent/EP4186527A4/en not_active Withdrawn
- 2021-06-18 WO PCT/JP2021/023149 patent/WO2021256555A1/ja not_active Ceased
- 2021-06-18 AU AU2021292932A patent/AU2021292932A1/en not_active Abandoned
- 2021-06-18 CR CR20230014A patent/CR20230014A/es unknown
- 2021-06-18 JP JP2022531930A patent/JP7250219B2/ja active Active
- 2021-06-18 KR KR1020227039674A patent/KR102594943B1/ko active Active
- 2021-06-18 BR BR112022025536A patent/BR112022025536A2/pt unknown
-
2022
- 2022-12-16 CL CL2022003622A patent/CL2022003622A1/es unknown
-
2023
- 2023-03-20 JP JP2023043678A patent/JP2023078311A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| CA2945902C (en) | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof | |
| JPWO2021256555A5 (https=) | ||
| US12398209B2 (en) | Methods of treating cancers with antagonistic anti-PD-1 antibodies | |
| JP2021168661A (ja) | 三重特異性結合タンパク質と使用方法 | |
| Kaiser | Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline | |
| TWI908743B (zh) | 抗dll3藥劑之給藥方案 | |
| JP2018012705A (ja) | 抗ｖｅｇｆ抗体での治療 | |
| US20230101029A1 (en) | Methods of using il-33 protein in treating cancers | |
| JPH08504172A (ja) | 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法 | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| JP2019514846A (ja) | 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用 | |
| CN102170908A (zh) | 向个体的肿瘤引流淋巴结递送cd40激动剂 | |
| CN103536917B (zh) | 干扰素在治疗肿瘤中的用途及相关的产品和方法 | |
| CN113271964A (zh) | 化脓性汗腺炎治疗中使用的抗cd40抗体 | |
| WO2019184282A1 (zh) | 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用 | |
| JPWO2020113194A5 (https=) | ||
| CN105251004A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| US20250340634A1 (en) | Dosage regimens for anti-cd19 agents and uses thereof | |
| Parrondo et al. | Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives | |
| Magarotto et al. | Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins | |
| BR112020017445A2 (pt) | anticorpos anti cd6 para tratar asma severa | |
| Tacchetti et al. | Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma | |
| JP7539609B2 (ja) | 抗－ｃｄ３００ｃ単クローン抗体を含むがん予防または治療用組成物 | |
| JP2025138745A (ja) | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 |